Switch to:
Progenics Pharmaceuticals, Inc. (NAS:PGNX)
Additional Paid-In Capital
$548.51 Mil (As of Dec. 2013)

Progenics Pharmaceuticals, Inc.'s quarterly additional paid-in capital increased from Jun. 2013 ($541.76 Mil) to Sep. 2013 ($547.87 Mil) and increased from Sep. 2013 ($547.87 Mil) to Dec. 2013 ($548.51 Mil).

Progenics Pharmaceuticals, Inc.'s annual additional paid-in capital increased from Dec. 2011 ($463.44 Mil) to Dec. 2012 ($493.61 Mil) and increased from Dec. 2012 ($493.61 Mil) to Dec. 2013 ($548.51 Mil).


Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)*Shares Outstanding

Related Terms

Shares Outstanding

Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Progenics Pharmaceuticals, Inc. Annual Data

AdditionalPaidInCapital 153.47306.09321.32401.50422.09439.94453.35463.44493.61548.51

Progenics Pharmaceuticals, Inc. Quarterly Data

AdditionalPaidInCapital 461.28463.44466.13468.41469.39493.61505.58541.76547.87548.51
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial